Effects of different chemotherapy regimens on survival for advanced cervical cancer: Systematic review and meta-analysis

Tzioras, Spyridon; Pavlidis, Nicholas; Paraskevaidis, Evangelos; Ioannidis, John P. A.

doi:10.1016/j.ctrv.2006.09.007

Cited by 41 publications

(27 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A number of agents have been combined with cisplatin and explored in evidence-based phase 3 randomized trials in the management of recurrent or metastatic cervix cancer [2,3,4,5]. Adding paclitaxel to cisplatin was shown to improve the objective response rate and time to disease progression compared to single agent cisplatin, but the trial revealed no evidence of an improvement in overall survival associated with the delivery of the combination [8].…”

Section: The Role Of Chemotherapy Without Concurrent Radiation In Thementioning

confidence: 99%

See 1 more Smart Citation

Chemoradiation in the Management of Cervix Cancer: Current Status and Future Directions

Markman

2013

Oncology

View full text Add to dashboard Cite

Cytotoxic chemotherapy has been shown to have only a very modest impact on outcome in recurrent, persistent, or metastatic cervix cancer. Despite this fact, when cisplatin is administered concurrently with external beam radiation as a ‘chemosensitizing’ strategy, both progression-free and overall survival have been shown in multiple evidence-based randomized trials to be improved compared to the delivery of radiation alone. Ongoing research in this area has focused on improving the drug component of this strategy and on following the concurrent chemoradiation with systemic (‘adjuvant’) therapy.

show abstract

Section: The Role Of Chemotherapy Without Concurrent Radiation In Thementioning

confidence: 99%

“…Despite several decades of intensive research, including the conduct of numerous phase 3 randomized trials, the impact of chemotherapy on the natural history of advanced cervix cancer is appreciated to be (at best) quite modest [1,2,3,4,5,6,7]. …”

Section: The Role Of Chemotherapy Without Concurrent Radiation In Thementioning

confidence: 99%

Chemoradiation in the Management of Cervix Cancer: Current Status and Future Directions

Markman

2013

Oncology

View full text Add to dashboard Cite

show abstract

“…Current treatments for cervical cancer are radiotherapy, chemotherapy and surgery; and cisplatin-based treatments are the most popular regimens (Tzioras et al, 2007;Diaz-Padilla et al, 2013). However, severe side effects such as haematological toxicity (bone-marrow depression, neutropenia, thrombocytopenia and anaemia), nephrotoxicity, neurotoxicity and chemoresistance have limited its clinical use (Maduro et al, 2003;Das et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

“…Cervical cancer is the second leading cause of cancer deaths among females worldwide, with approximately half a million new cases and over 200 000 deaths each year; and prognosis for advanced stage disease is poor (Tzioras et al, 2007;Zong et al, 2015). Current treatments for cervical cancer are radiotherapy, chemotherapy and surgery; and cisplatin-based treatments are the most popular regimens (Tzioras et al, 2007;Diaz-Padilla et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

Folate-modified, cisplatin-loaded lipid carriers for cervical cancer chemotherapy

et al. 2015

View full text Add to dashboard Cite

Background: Cervical cancer chemotherapy calls for the efficiently delivery of anticancer drug into cancer cells by nanoparticles. In this study, folate (FA) modified, cisplatin (CIS)-loaded nanostructured lipid carriers (NLCs) were constructed and evaluated. Methods: FA containing polyethylene glycol (PEG)-distearoylphosphatidylethanolamine (DSPE) (FA-PEG-DSPE) was synthesized. FA-PEG-DSPE modified, CIS-loaded NLCs (FA-CIS-NLCs) were prepared. Their particle size, zeta potential, drug encapsulation efficiency (EE) and in vitro delivery behavior were evaluated. In vitro cytotoxicity study of FA-CIS-NLCs was tested in human cervix adenocarcinoma cell line (HeLa cells). In vivo anti-tumor efficacies of the carriers were evaluated on a mice-bearing cervical cancer model.

show abstract

“…Radiotherapy (RT) is the major treatment modality for invasive cervical carcinomas; however, the prognosis is poor in advanced uterine cervical carcinoma (2,3).…”

Section: Introductionmentioning

confidence: 99%

Concurrent chemoradiotherapy with nedaplatin in patients with stage IIA to IVA cervical carcinoma

Fujioka

Yasuoka

Koizumi

et al. 2012

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. The present study aimed to evaluate the efficacy and toxicities of nadaplatin-based concurrent chemoradiotherapy (CCRT) in patients with stage IIA to IVA cervical carcinoma. Patients with an International Federation of Gynecology and Obstetrics (FIGO) stage IIA to IVA cervical carcinoma were treated with nadaplatin-based CCRT, using high-dose rate intracavitary brachytherapy (HDR-ICBT) or radiotherapy (RT) alone, in patients with FIGO stage IIA to IVA cervical carcinoma. CCRT with nedaplatin (80 mg/m 2 ) was administered on Days 1 and 29. The records of 17 women treated either with nadaplatin-based CCRT using HSR-ICBT (n=8) or RT alone (n= 9), for stage IIA to IVA cervical carcinoma were retrospectively reviewed. The activity and toxicity were compared in the two treatment groups. Progression-free survival (PFS) and overall survival (OS) were the main endpoints. The 5-year overall survival rates in the CCRT and RT groups were 68.6 and 77.8%, respectively. The median OS of the CCRT and RT groups was 38.5 and 27.3 months, respectively. There was no significant difference in either PFS (P= 0.618) or OS (P= 0.231). The most common grade 3-4 or higher toxicities in the CCRT groups were leuko-/neutropenia (37.5%). The frequency of acute grade 3-4 toxicity was higher in the CCRT compared to the RT group. However, no statistically significant difference was observed. Nedaplatin-based CCRT was safely performed. Although the prognosis of patients with FIGO stage IIA to IVA cervical carcinoma was not significantly improved, fewer distant relapses were observed in this treatment. Consequently, nedaplatin-based CCRT may be considered as a potential alternative to cisplatin-based CCRT in this patient population.

show abstract

Effects of different chemotherapy regimens on survival for advanced cervical cancer: Systematic review and meta-analysis

Cited by 41 publications

References 75 publications

Chemoradiation in the Management of Cervix Cancer: Current Status and Future Directions

Chemoradiation in the Management of Cervix Cancer: Current Status and Future Directions

Folate-modified, cisplatin-loaded lipid carriers for cervical cancer chemotherapy

Concurrent chemoradiotherapy with nedaplatin in patients with stage IIA to IVA cervical carcinoma

Contact Info

Product

Resources

About